Eli Lilly and Company will present new cardiometabolic data at the European Association for the Study of Diabetes (EASD) 2026 meeting. The presentations feature Foundayo (orforglipron), the investigational eloraTZP, and retatrutide.
Lilly will highlight pivotal Phase 3 results from the TRIUMPH-2 study of retatrutide. This investigational triple hormone receptor agonist targeted adults with type 2 diabetes and obesity or overweight. Participants lost an average of 49.6 pounds. This weight loss represents 20.8% of total body weight. The trial also demonstrated significant A1C reductions.
The company will also present positive data for Foundayo. Additionally, Lilly will share Phase 2 results for eloraTZP.